Uveitis - Pipeline Review, H1 2017

Transcription

1 Report Information More information from: Uveitis - Pipeline Review, H Report / Search Code: WGR Publish Date: 28 April, 2017 Price 1-user PDF : $ Site PDF : $ Enterprise PDF : $ Description: Uveitis - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis

2 (Ophthalmology) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Contents: Table of Contents Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Uveitis - Overview 8 Uveitis - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 19 Uveitis - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Uveitis - Companies Involved in Therapeutics Development 30 2-BBB Medicines BV 30 Aciont Inc 30 Aldeyra Therapeutics Inc 31 Apitope International NV 31 Astellas Pharma Inc 32 Bionomics Ltd 32 Bristol-Myers Squibb Company 33 Can-Fite BioPharma Ltd 33 Clearside BioMedical Inc 34 Coherus BioSciences Inc 34 Elasmogen Ltd 35 Endocyte Inc 35 Enzo Biochem Inc 36 EyeGate Pharmaceuticals Inc 36 Eyevensys SAS 37 F. Hoffmann-La Roche Ltd 37 HanAll Biopharma Co Ltd 38 Icon Bioscience Inc 38 Idera Pharmaceuticals Inc 39 InnoMedica Holding AG 39 KPI Therapeutics Inc 40 Midatech Pharma Plc 40 Mitotech SA 41 Nemus Bioscience Inc 41 Neuroptis Biotech 42 Novartis AG 42 Oculis ehf 43 OncoNOx ApS 43 Orchid Pharma Ltd 44

3 OSE Immunotherapeutics 44 Palatin Technologies Inc 45 Panacea Biotec Ltd 45 Panoptes Pharma GesmbH 46 Pfizer Inc 46 psivida Corp 47 Re-Pharm Ltd 47 Regeneron Pharmaceuticals Inc 48 Sandoz International GmbH 48 Santen Pharmaceutical Co Ltd 49 SynDevRx Inc 49 TxCell SA 50 Uveitis - Drug Profiles 51 2B Drug Profile 51 abatacept - Drug Profile 53 adalimumab biosimilar - Drug Profile 60 adalimumab biosimilar - Drug Profile 61 adalimumab biosimilar - Drug Profile 63 adalimumab biosimilar - Drug Profile 64 ADX Drug Profile 65 Antisense Oligonucleotide to Inhibit NLRP3 for Uveitis, Cystitis and Inflammatory Disorders - Drug Profile 70 Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile 71 ANV Drug Profile 72 ATXUV-1 - Drug Profile 73 B27-PD - Drug Profile 74 BNC Drug Profile 75 celecoxib - Drug Profile 76 Col-Treg - Drug Profile 79 CVX Drug Profile 81 cyclosporine SR - Drug Profile 82 dalazatide - Drug Profile 83 dexamethasone acetate - Drug Profile 88 dexamethasone acetate - Drug Profile 93 dexamethasone acetate - Drug Profile 95 dexamethasone sodium phosphate - Drug Profile 96 Drug for Chronic Uveitis - Drug Profile 98 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 99 EBI Drug Profile 100 EC Drug Profile 101 ELN-21 - Drug Profile 102 ELN-22 - Drug Profile 103 EYS Drug Profile 104 fluocinolone acetonide SR - Drug Profile 105 FR Drug Profile 113 Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 116 HL Drug Profile 117 HO-10 - Drug Profile 118 IVMED-10 - Drug Profile 119 IVMED-20 - Drug Profile 120 KPI Drug Profile 121 latanoprost SR - Drug Profile 122 LME Drug Profile 123 lodamin - Drug Profile 124 methotrexate - Drug Profile 125 NB Drug Profile 126 NOP-3 - Drug Profile 127 OX Drug Profile 128 piclidenoson - Drug Profile 129 PL Drug Profile 138 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 139 PP Drug Profile 141 PPL Drug Profile 143 RP Drug Profile 145 sarilumab - Drug Profile 146 sirolimus - Drug Profile 153

4 Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile 156 Small Molecules for Posterior Uveitis - Drug Profile 157 Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 158 Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile 159 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 160 tesidolumab - Drug Profile 162 triamcinolone acetonide - Drug Profile 164 Uveitis - Dormant Projects 170 Uveitis - Discontinued Products 173 Uveitis - Product Development Milestones 174 Featured News & Press Releases 174 Appendix 181 Methodology 181 Coverage 181 Secondary Research 181 Primary Research 181 Expert Panel Validation 181 Contact Us 181 Disclaimer 182 List of Tables Number of Products under Development for Uveitis, H Number of Products under Development by Companies, H Number of Products under Development by Companies, H (Contd..1), H Number of Products under Development by Companies, H (Contd..2), H Number of Products under Development by Universities/Institutes, H Products under Development by Companies, H Products under Development by Companies, H (Contd..1), H Products under Development by Companies, H (Contd..2), H Products under Development by Companies, H (Contd..3), H Products under Development by Universities/Institutes, H Number of Products by Stage and Target, H Number of Products by Stage and Target, H (Contd..1), H Number of Products by Stage and Mechanism of Action, H Number of Products by Stage and Mechanism of Action, H (Contd..1), H Number of Products by Stage and Route of Administration, H Number of Products by Stage and Molecule Type, H Uveitis - Pipeline by 2-BBB Medicines BV, H Uveitis - Pipeline by Aciont Inc, H Uveitis - Pipeline by Aldeyra Therapeutics Inc, H Uveitis - Pipeline by Apitope International NV, H Uveitis - Pipeline by Astellas Pharma Inc, H Uveitis - Pipeline by Bionomics Ltd, H Uveitis - Pipeline by Bristol-Myers Squibb Company, H Uveitis - Pipeline by Can-Fite BioPharma Ltd, H Uveitis - Pipeline by Clearside BioMedical Inc, H Uveitis - Pipeline by Coherus BioSciences Inc, H Uveitis - Pipeline by Elasmogen Ltd, H Uveitis - Pipeline by Endocyte Inc, H Uveitis - Pipeline by Enzo Biochem Inc, H Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H Uveitis - Pipeline by Eyevensys SAS, H Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H Uveitis - Pipeline by HanAll Biopharma Co Ltd, H Uveitis - Pipeline by Icon Bioscience Inc, H Uveitis - Pipeline by Idera Pharmaceuticals Inc, H Uveitis - Pipeline by InnoMedica Holding AG, H Uveitis - Pipeline by KPI Therapeutics Inc, H Uveitis - Pipeline by Midatech Pharma Plc, H Uveitis - Pipeline by Mitotech SA, H Uveitis - Pipeline by Nemus Bioscience Inc, H Uveitis - Pipeline by Neuroptis Biotech, H Uveitis - Pipeline by Novartis AG, H Uveitis - Pipeline by Oculis ehf, H Uveitis - Pipeline by OncoNOx ApS, H Uveitis - Pipeline by Orchid Pharma Ltd, H Uveitis - Pipeline by OSE Immunotherapeutics, H Uveitis - Pipeline by Palatin Technologies Inc, H Uveitis - Pipeline by Panacea Biotec Ltd, H1 2017

5 Uveitis - Pipeline by Panoptes Pharma GesmbH, H Uveitis - Pipeline by Pfizer Inc, H Uveitis - Pipeline by psivida Corp, H Uveitis - Pipeline by Re-Pharm Ltd, H Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H Uveitis - Pipeline by Sandoz International GmbH, H Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H Uveitis - Pipeline by SynDevRx Inc, H Uveitis - Pipeline by TxCell SA, H Uveitis - Dormant Projects, H Uveitis - Dormant Projects, H (Contd..1), H Uveitis - Dormant Projects, H (Contd..2), H Uveitis - Discontinued Products, H List of Figures Number of Products under Development for Uveitis, H Number of Products under Development by Companies, H Number of Products under Development by Universities/Institutes, H Number of Products by Top 10 Targets, H Number of Products by Stage and Top 10 Targets, H Number of Products by Top 10 Mechanism of Actions, H Number of Products by Stage and Top 10 Mechanism of Actions, H Number of Products by Routes of Administration, H Number of Products by Stage and Routes of Administration, H Number of Products by Top 10 Molecule Types, H Number of Products by Stage and Top 10 Molecule Types, H wiseguyreports.com / Phone (US) (UK)